Page URL:

On the horizon: two new breast cancer tests

15 August 2005
By BioNews
Appeared in BioNews 321

A new test could enable doctors to more accurately predict if women are at a higher risk of carryingmutated BRCA1 breast cancer gene. This may help women who do not know if the disease runs in their family decide whether they need to be tested for the mutated gene. The current criteria for referral for this testing includes knowledge of a strong family history of breast or ovarian cancer.

People carrying a faulty version of the BRCA1 gene have an 80 per cent chance of developing cancer in the breast or ovary, a 50 per cent chance of developing a second breast cancer and a 40 per cent chance of developing a second cancer in the ovary. Faults in the BRCA1 and BRCA2 genes increase the risk of developing cancer because both normally protect the cells from cancer-causing changes. However, fewer than five per cent of all breast cancers are due to BRCA1 and BRCA2 gene mutations.

In the latest study, scientists from Cancer Research UK in Cambridge, Leeds and Manchester, along with others from around the world tested 200 breast tumours for a specific marker. They found that 56 per cent of all BRCA1 gene mutation carriers tested positive for this marker.

'Many women who don't know their family history of breast cancer can be anxious about their children's risk when diagnosed. We hope that this novel marker test can be further developed to identify more patients in the future who should consider genetic testing but who do not fit the current criteria', said Professor Doug Easton from Cancer Research UK's genetic epidemiology unit in Cambridge.

Meanwhile in Germany, researchers may have found a way to tell whether a breast cancer patient will respond positively to pre-operative systemic chemotherapy (PST).

Researchers led by Olga Modlich at the University of Dusseldorf and Bayer HealthCare AG found 57 'predictor' genes by analysing samples of breast tissue from five healthy people and 56 breast cancer patients by DNA microarray analysis. Thirty-one of the 'predictor' genes are associated with a positive response to PST and 26 are associated with a poor response.

The genes were then used to predict the outcome of PST in 27 patients. They correctly predicted the outcome of the treatment in all cases of partial remission and 75 per cent of cases in complete remission of primary tumours.

If this test is further developed, it could be an important resource to help doctors identify which drugs will be the most appropriate for which patients.

Gene-test clue to cancer treatment
The Scotsman |  9 August 2005
New test for breast cancer gene
The Daily Mail |  10 August 2005
Patient's genes can predict response to chemotherapy for breast cancer
Medical News Today |  9 August 2005
Screening hope for genetic cancer
The Daily Telegraph |  10 August 2005
8 September 2005 - by BioNews 
The US Preventive Services Task Force has published guidelines on assessing the risk of familial breast and ovarian cancer. It states that genetic counselling is only appropriate for women whose family history suggests they may have inherited a mutation in the BRCA1 and BRCA2 breast cancer genes. The recommendations were...
24 October 2003 - by BioNews 
Women who inherit mutations in one of two genes involved in inherited breast cancer have an 82 per cent lifetime risk of developing the disease, according to a new study carried out by the New York Breast Cancer Study Group (NYBCS). They found that women who have a genetic mutation...
4 August 2003 - by BioNews 
A new study, published in The Lancet, shows that it may be possible to determine whether breast cancer patients will respond to cancer treatment by peforming a genetic test on them. Establishing if a woman will or will not respond to a particular drug could save many women from undergoing...
21 May 2001 - by BioNews 
A new test has been developed that will make it much easier, faster and also cheaper to detect some genetic abnormalities that are associated with an increased risk of breast cancer. The American scientists who have developed the test say that it may have the potential to transform future breast...
20 November 2000 - by BioNews 
The UK government is finalising a deal that will allow NHS doctors to carry out tests on two patented genes involved in breast cancer, without paying royalty fees to British licence-holders Rosgen. Although the details of the deal have yet to be agreed, Rosgens say that in the interim, NHS...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.